1,4-dihydro-4-oxo-3-quinolone derivatives as selectively toxic mammalian antibacterial agents
CA 2026972 A1 · Owner: Pfizer Inc. · Inventors: Mcguirk, Paul R.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
1,4-DIHYDRO-4-OXO-3-QUINOLINE DERIVATIVES AS SELECTIVE MAMMALIAN ANTIBACTERIAL AGENTS ABSTRACT, Compounds of the formula, and the pharmaceutically acceptable salts thereof wherein Q, X, and R are as defined below. The compounds of formula I are broad spectrum mammalian antibacterial agents and exhibit favourable selectivity against procaryotic cells. Q is methyl ethyl, hydroxyethyl or hydrogen; R is hydrogen (C1-C3)alkyl benzyl, (C1-C3)alkanoyloxymethyl, (C1-C3)alkanoyloxyethyl benzoyloxy-, methyl, benzoyloxyethyl, or 5-(C1-C3)alkyl-2-oxo-1,3-dioxolen- 4-ylmethyl, and Y is cyclopropyl or substituted cyclopropyl wherein said substituted cyclopropyl is substituted with one to three …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 4, 1990. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended October 4, 2010.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 4, 2012.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.